Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Amgen 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen 2Q

2Q Revenues: $3.8 billion (+1%)

2Q Earnings: $941 million (-8%)

YTD Revenues: $7.4 billion (-1%)

YTD Earnings: $2.0 billion (-2%)

Comments: U.S. sales dropped 1% in 2Q08 to $2.8 billion while international sales rose 17%. Aranesp sales fell 13% in the quarter due to regulatory and reimbursement changes, while Epogen sales were flat. Neulasta and Neupogen combined sales rose 15% to $1.2 billion, driven primarily by Neulasta. Enbrel sales increased 2% to $841 million, as competition curtailed sales growth. Sensipar sales grew 39% to $150 million. R&D expenses were flat, partly as a result of licensing out several R&D programs to Daiichi Sankyo and Takeda.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters